Brief Article
Copyright ©2011 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Jul 21, 2011; 17(27): 3242-3247
Published online Jul 21, 2011. doi: 10.3748/wjg.v17.i27.3242
Symptom-based tendencies of Helicobacter pylori eradication in patients with functional dyspepsia
Ling Lan, Jing Yu, Yu-Long Chen, Ya-Li Zhong, Hao Zhang, Chang-He Jia, Yuan Yuan, Bo-Wei Liu
Ling Lan, Jing Yu, Hao Zhang, Chang-He Jia, Yuan Yuan, Bo-Wei Liu, Department of Gastroenterology, the People’s Hospital of Henan Province, Zhengzhou 450003, Henan Province, China
Yu-Long Chen, Department of Gastroenterology, the Fist Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, Henan Province, China
Ya-Li Zhong, Department of Gastroenterology, the Second Affiliated Hospital, Zhengzhou University, Zhengzhou 450014, Henan Province, China
Author contributions: Lan L, Chen YL and Yu J designed the study proposal; Lan L, Yu J, Chen YL, Zhong YL, Zhang H and Jia CH treated the patients, collected and provided patient’s data; Liu BW and Yuan Y analyzed the data; Lan L and Liu BW wrote the paper.
Supported by The Endoscope Center of the People’s Hospital of Henan Province, Zhengzhou, China
Correspondence to: Jing Yu, Professor of Medicine, Department of Gastroenterology, the People’s Hospital of Henan Province, No. 7, Weiwu Road, Zhengzhou 450003, Henan Province, China. jingyu.123@hotmail.com
Telephone: +86-371-65580603 Fax: +86-371-65964376
Received: November 5, 2010
Revised: November 24, 2010
Accepted: December 1, 2010
Published online: July 21, 2011
Abstract

AIM: To investigate whether there were symptom-based tendencies in the Helicobacter pylori (H. pylori) eradication in functional dyspepsia (FD) patients.

METHODS: A randomized, single-blind, placebo-controlled study of H. pylori eradication for FD was conducted. A total of 195 FD patients with H. pylori infection were divided into two groups: 98 patients in the treatment group were treated with rabeprazole 10 mg twice daily for 2 wk, amoxicillin 1.0 g and clarithromycin 0.5 g twice daily for 1 wk; 97 patients in the placebo group were given placebos as control. Symptoms of FD, such as postprandial fullness, early satiety, nausea, belching, epigastric pain and epigastric burning, were assessed 3 mo after H. pylori eradication.

RESULTS: By per-protocol analysis in patients with successful H. pylori eradication, higher effective rates of 77.2% and 82% were achieved in the patients with epigastric pain and epigastric burning than those in the placebo group (P < 0.05). The effective rates for postprandial fullness, early satiety, nausea and belching were 46%, 36%, 52.5% and 33.3%, respectively, and there was no significant difference from the placebo group (39.3%, 27.1%, 39.1% and 31.4%) (P > 0.05). In 84 patients who received H. pylori eradication therapy, the effective rates for epigastric pain (73.8%) and epigastric burning (80.7%) were higher than those in the placebo group (P < 0.05). The effective rates for postprandial fullness, early satiety, nausea and belching were 41.4%, 33.3%, 50% and 31.4%, respectively, and did not differ from those in the placebo group (P > 0.05). By intention-to-treat analysis, patients with epigastric pain and epigastric burning in the treatment group achieved higher effective rates of 60.8% and 65.7% than the placebo group (33.3% and 31.8%) (P < 0.05). The effective rates for postprandial fullness, early satiety, nausea and belching were 34.8%, 27.9%, 41.1% and 26.7% respectively in the treatment group, with no significant difference from those in the placebo group (34.8%, 23.9%, 35.3% and 27.1%) (P > 0.05).

CONCLUSION: The efficacy of H. pylori eradication has symptom-based tendencies in FD patients. It may be effective in the subgroup of FD patients with epigastric pain syndrome.

Keywords: Helicobacter pylori, Functional dyspepsia, Eradication, Symptom